Irum Khan

1.4k total citations
47 papers, 805 citations indexed

About

Irum Khan is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Irum Khan has authored 47 papers receiving a total of 805 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Hematology, 17 papers in Molecular Biology and 9 papers in Genetics. Recurrent topics in Irum Khan's work include Acute Myeloid Leukemia Research (22 papers), Hematopoietic Stem Cell Transplantation (8 papers) and Acute Lymphoblastic Leukemia research (7 papers). Irum Khan is often cited by papers focused on Acute Myeloid Leukemia Research (22 papers), Hematopoietic Stem Cell Transplantation (8 papers) and Acute Lymphoblastic Leukemia research (7 papers). Irum Khan collaborates with scholars based in United States, Spain and France. Irum Khan's co-authors include John D. Crispino, Sébastien Malinge, Andrei L. Gartel, Santosh L. Saraf, Nadim Mahmud, John G. Quigley, Damiano Rondelli, Pritesh Patel, Marianna Halasi and Andreas Krueger and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

In The Last Decade

Irum Khan

43 papers receiving 793 citations

Peers

Irum Khan

HEMAT

GENET

ONCOL

PPCH

Victoria Bedell United States

Julie Aldridge United States

Nader Al‐Dewik Qatar

Kristin Page United States

Hussein A. Abbas United States

A. O’Meara Ireland

Juan J. Haro‐Mora United States

Catharina Dhooge Belgium

Jenny Chia Australia

Christina Fagerberg Denmark

Victoria Bedell United States

Irum Khan

218 ×0.7

HEMAT

431 ×1.5

156 ×0.7

GENET

181 ×1.6

ONCOL

192 ×1.8

PPCH

Citations per year, relative to Irum Khan Irum Khan (= 1×) peers Victoria Bedell

Countries citing papers authored by Irum Khan

Since Specialization

Citations

This map shows the geographic impact of Irum Khan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Irum Khan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Irum Khan more than expected).

Fields of papers citing papers by Irum Khan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Irum Khan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Irum Khan. The network helps show where Irum Khan may publish in the future.

Co-authorship network of co-authors of Irum Khan

This figure shows the co-authorship network connecting the top 25 collaborators of Irum Khan. A scholar is included among the top collaborators of Irum Khan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Irum Khan. Irum Khan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Raghuwanshi, Sanjeev, Xu Zhang, Zarema Arbieva, et al.. (2024). Novel FOXM1 inhibitor STL001 sensitizes human cancers to a broad-spectrum of cancer therapies. Cell Death Discovery. 10(1). 211–211. 9 indexed citations

Murga‐Zamalloa, Carlos, Ankit I. Mehta, Irum Khan, et al.. (2024). Characterization of T-/natural killer cell lymphoproliferative neoplasms associated with systemic, chronic, active Epstein-Barr virus in adults: A report of 5 cases in a Western population. American Journal of Clinical Pathology. 161(6). 586–597. 1 indexed citations

Hantel, Andrew, Yating Wang, Ivy Abraham, et al.. (2024). Identifying eligibility criteria that perpetuate race/ethnic disparities in acute myeloid leukemia (AML) clinical trial participation.. Journal of Clinical Oncology. 42(16_suppl). 1589–1589.

Khan, Irum, Mohammed A. Amin, Elizabeth A. Eklund, & Andrei L. Gartel. (2024). Regulation of HOX gene expression in AML. Blood Cancer Journal. 14(1). 42–42. 10 indexed citations

Abraham, Ivy, Madelyn Burkart, Hamed Rahmani Youshanlouei, et al.. (2024). Air pollutant impact on disease characteristics and outcomes in patients with acute myeloid leukemia. Blood Advances. 8(17). 4647–4650. 2 indexed citations

Othus, Megan, Corentin Orvain, Eduardo Rodríguez‐Arbolí, et al.. (2024). Impact of socioeconomic disparities on outcomes in adults undergoing allogeneic hematopoietic cell transplantation for acute myeloid leukemia. Leukemia. 38(4). 865–876. 4 indexed citations

Othus, Megan, Corentin Orvain, Eduardo Rodríguez‐Arbolí, et al.. (2023). Impact of Socioeconomic Disparities on Outcomes in Adults Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia. Blood. 142(Supplement 1). 3809–3809. 1 indexed citations

Hantel, Andrew, Marlise R. Luskin, Irum Khan, et al.. (2023). Use, variability, and justification of eligibility criteria for phase II and III clinical trials in acute leukemia. Haematologica. 109(4). 1046–1052. 5 indexed citations

Singaram, Indira, Ashutosh Sharma, Shashank Pant, et al.. (2022). Targeting lipid–protein interaction to treat Syk-mediated acute myeloid leukemia. Nature Chemical Biology. 19(2). 239–250. 14 indexed citations

10.

Chesnokov, Mikhail S., Marianna Halasi, Zarema Arbieva, et al.. (2021). Novel FOXM1 inhibitor identified via gene network analysis induces autophagic FOXM1 degradation to overcome chemoresistance of human cancer cells. Cell Death and Disease. 12(7). 704–704. 20 indexed citations

11.

Chesnokov, Mikhail S., et al.. (2021). FOXM1-AKT Positive Regulation Loop Provides Venetoclax Resistance in AML. Frontiers in Oncology. 11. 696532–696532. 21 indexed citations

12.

Abraham, Ivy, Anand Patel, John P. Galvin, et al.. (2021). Impact of race on outcomes in intermediate-risk acute myeloid leukemia. Cancer Causes & Control. 32(7). 705–712. 9 indexed citations

13.

Mohapatra, Gayatry, et al.. (2021). Extended treatment response to imatinib in Rosai‐Dorfman disease. European Journal Of Haematology. 106(6). 868–870. 4 indexed citations

14.

Saraf, Santosh L., Annie Oh, Pritesh Patel, et al.. (2018). Haploidentical Peripheral Blood Stem Cell Transplantation Demonstrates Stable Engraftment in Adults with Sickle Cell Disease. Biology of Blood and Marrow Transplantation. 24(8). 1759–1765. 43 indexed citations

15.

Halasi, Marianna, Binal N. Shah, Renáta Váraljai, et al.. (2018). Honokiol is a FOXM1 antagonist. Cell Death and Disease. 9(2). 84–84. 44 indexed citations

16.

Khan, Irum, Marianna Halasi, Anand Patel, et al.. (2018). FOXM1 contributes to treatment failure in acute myeloid leukemia. JCI Insight. 3(15). 19 indexed citations

17.

Sweiss, Karen, Jennifer M. Anderson, Annie Oh, et al.. (2017). A prospective study of intravenous pentamidine for PJP prophylaxis in adult patients undergoing intensive chemotherapy or hematopoietic stem cell transplant. Bone Marrow Transplantation. 53(3). 300–306. 10 indexed citations

18.

Khan, Irum, Ardaman Shergill, Santosh L. Saraf, et al.. (2016). Outcome Disparities in Caucasian and Non-Caucasian Patients With Myeloproliferative Neoplasms. Clinical Lymphoma Myeloma & Leukemia. 16(6). 350–357. 13 indexed citations

19.

Khan, Irum, Zan Huang, Qing Wen, et al.. (2013). AKT is a therapeutic target in myeloproliferative neoplasms. Leukemia. 27(9). 1882–1890. 62 indexed citations

20.

Marečková, Klára, Jennifer S. Perrin, Irum Khan, et al.. (2012). Hormonal contraceptives, menstrual cycle and brain response to faces. Social Cognitive and Affective Neuroscience. 9(2). 191–200. 60 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact